NIHR reveals phase 1/2 trial to evaluate an investigational vaccine for mpox in the UK More than 3,700 cases of mpox have been identified in the UK since May 2022
First UK patients receive experimental mRNA therapy for cancer in global trial The phase 1/2 Mobilize trial is evaluating the safety and efficacy of mRNA-4359